amitriptyline has been researched along with Body Weight in 72 studies
Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.
amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The study describes a sequential analysis of depression-related physical symptoms and their relationship to imipramine and amitriptyline plasma levels over 4 weeks of treatment in 79 unipolar and bipolar patients hospitalized for major depressive disorder." | 9.07 | The pattern of physical symptom changes in major depressive disorder following treatment with amitriptyline or imipramine. ( Bowden, CL; Casper, RC; Davis, JM; Hanin, I; Katz, MM; Koslow, SH, 1994) |
| "Fluoxetine, a specific serotonin reuptake inhibitor, was compared to amitriptyline in the treatment of 51 outpatients with primary major depressive disorder." | 9.05 | A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. ( Chouinard, G, 1985) |
| "The tricyclic antidepressant drug amitriptyline was evaluated as a short-term treatment of anorexia nervosa patients." | 9.05 | Amitriptyline in the treatment of anorexia nervosa: a double-blind, placebo-controlled study. ( Biederman, J; Ferber, RA; Harmatz, JS; Harper, GP; Herzog, DB; Orsulak, PJ; Rivinus, TM; Rosenbaum, JF; Schildkraut, JJ; Tondorf, R, 1985) |
| "The effect of hypothyroidism induced by thiamazole on the toxicity of amitriptyline was studied in chick embryos." | 7.73 | Influence of hypothyroidism induced by thiamazole on the toxicity of amitriptyline in chick embryos. ( Kanke, M; Yoshiyama, Y, 2006) |
| " Sprague-Dawley rats with adjuvant-induced arthritis were injected daily for 4 weeks with amitriptyline (10 mg/kg) or imipramine (10 mg/kg) or saline, beginning 21 days after the induction of arthritis." | 7.67 | Reduction of arthritis and pain behaviour following chronic administration of amitriptyline or imipramine in rats with adjuvant-induced arthritis. ( Besson, JM; Butler, SH; Godefroy, F; Weil-Fugazza, J, 1985) |
| "Bupropion treatment was rarely accompanied by reports of appetite change and had no statistically significant effect on caloric intake when compared to placebo." | 6.65 | Effects of bupropion on body weight. ( Cato, AE; Harto-Truax, N; Miller, LL; Sato, TL; Stern, WC, 1983) |
| "Amitriptyline was the most effective with regard to symptoms included in the factor Sleep Disturbances and-secondary maybe-towards some items included in the factor Somatization." | 6.65 | Amoxapine versus amitriptyline in endogenous depression. A double-blind study. ( Fruensgaard, K; Hansen, CE; Korsgaard, S; Nymgaard, K; Vaag, UH, 1979) |
| "Amitriptyline treatment either caused no change in food intake and body weight or slightly reduced levels in comparison to vehicle-treated controls." | 5.27 | Effects of chronic amitriptyline and desipramine on food intake and body weight in rats. ( Coscina, DV; Nobrega, JN, 1987) |
| "The study describes a sequential analysis of depression-related physical symptoms and their relationship to imipramine and amitriptyline plasma levels over 4 weeks of treatment in 79 unipolar and bipolar patients hospitalized for major depressive disorder." | 5.07 | The pattern of physical symptom changes in major depressive disorder following treatment with amitriptyline or imipramine. ( Bowden, CL; Casper, RC; Davis, JM; Hanin, I; Katz, MM; Koslow, SH, 1994) |
| "Fluoxetine, a specific serotonin reuptake inhibitor, was compared to amitriptyline in the treatment of 51 outpatients with primary major depressive disorder." | 5.05 | A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. ( Chouinard, G, 1985) |
| "The tricyclic antidepressant drug amitriptyline was evaluated as a short-term treatment of anorexia nervosa patients." | 5.05 | Amitriptyline in the treatment of anorexia nervosa: a double-blind, placebo-controlled study. ( Biederman, J; Ferber, RA; Harmatz, JS; Harper, GP; Herzog, DB; Orsulak, PJ; Rivinus, TM; Rosenbaum, JF; Schildkraut, JJ; Tondorf, R, 1985) |
| " Corresponding to increase in plasma ceramide, the HFD significantly increased the body weight gain, plasma leptin concentration, urinary total protein and albumin excretion, glomerular damage index, and adipose tissue ASMase activity compared with the LFD-fed mice." | 3.76 | Role of sphingolipid mediator ceramide in obesity and renal injury in mice fed a high-fat diet. ( Boini, KM; Li, PL; Poklis, JL; Xia, M; Zhang, C, 2010) |
| "The effect of hypothyroidism induced by thiamazole on the toxicity of amitriptyline was studied in chick embryos." | 3.73 | Influence of hypothyroidism induced by thiamazole on the toxicity of amitriptyline in chick embryos. ( Kanke, M; Yoshiyama, Y, 2006) |
| " Sprague-Dawley rats with adjuvant-induced arthritis were injected daily for 4 weeks with amitriptyline (10 mg/kg) or imipramine (10 mg/kg) or saline, beginning 21 days after the induction of arthritis." | 3.67 | Reduction of arthritis and pain behaviour following chronic administration of amitriptyline or imipramine in rats with adjuvant-induced arthritis. ( Besson, JM; Butler, SH; Godefroy, F; Weil-Fugazza, J, 1985) |
| "Adults with 3 to 12 migraines per month were randomized in a 1:1 ratio to receive an initial dose of 25 mg/d of either topiramate or amitriptyline, subsequently titrated to a maximum of 100 mg/d (or the maximum tolerated dose)." | 2.74 | Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. ( Banks, J; Biondi, D; Dodick, DW; Freitag, F; Greenberg, SJ; Hulihan, J; Rupnow, M; Saper, J; Xiang, J, 2009) |
| "Sertraline was associated with a statistically lower frequency of somnolence, dry mouth, constipation, ataxia, and pain and a higher frequency of nausea, anorexia, diarrhea/loose stools, and insomnia; thus, anticholinergic effects were less common and gastrointestinal effects were more common with sertraline than with amitriptyline." | 2.67 | Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. ( Claghorn, JL; Cohn, CK; Cohn, JB; Dessain, EC; Fabre, LF; Itil, TM; Lautin, A; Mendels, J; Shrivastava, R, 1990) |
| " After 6 weeks of treatment with a daily dosage of 600 mg femoxetine or 150 mg amitriptyline, no statistically significant differences between the 2 treatment groups were observed, either when using the HDS or the clinical global assessment scale." | 2.66 | Femoxetine and amitriptyline in general practice: a randomized double-blind group comparison. ( Jeppesen, K; Skrumsager, BK, 1986) |
| "Zimeldine tolerability was compared to amitriptyline and placebo in a large multicentre study performed at three clinical research units in the U." | 2.65 | Zimeldine tolerability in comparison to amitriptyline and placebo: findings from a multicentre trial. ( Claghorn, J; Gershon, S; Goldstein, BJ, 1983) |
| " The results of this study indicated that amitriptyline hydrochloride at a dosage of 150 mg at bedtime had significant antidepressant activity in this group of patients." | 2.65 | A placebo-controlled, double-blind trial of amitriptyline in bulimia. ( Groat, R; Mitchell, JE, 1984) |
| "Bupropion treatment was rarely accompanied by reports of appetite change and had no statistically significant effect on caloric intake when compared to placebo." | 2.65 | Effects of bupropion on body weight. ( Cato, AE; Harto-Truax, N; Miller, LL; Sato, TL; Stern, WC, 1983) |
| " Patients fulfilling defined admission criteria were randomly allocated to treatment with evening dosage of either 50 mg of the sustained release preparation or 75 mg of dothiepin for the first week of the trial." | 2.65 | Clinical trial comparison of a sustained release form of amitriptyline with dothiepin. ( Dorman, T, 1980) |
| "Amitriptyline was the most effective with regard to symptoms included in the factor Sleep Disturbances and-secondary maybe-towards some items included in the factor Somatization." | 2.65 | Amoxapine versus amitriptyline in endogenous depression. A double-blind study. ( Fruensgaard, K; Hansen, CE; Korsgaard, S; Nymgaard, K; Vaag, UH, 1979) |
| "Mirtazapine is an antidepressant approved for the treatment of major depressive disorder." | 1.38 | Antidepressant use in underweight older adults. ( Avena-Woods, C; Hilas, O, 2012) |
| "Treatment of chlorpromazine and morphine during food deprivation did not provide a preventive effect in the development of convulsions observed after food intake in fasted animals." | 1.36 | Scopolamine-induced convulsions in fasted mice after food intake: evaluation of the sedative effect in the suppression of convulsions. ( Baran, E; Enginar, N; Karamürsel, Y; Nurten, A; Zengin, A, 2010) |
| "Amitriptyline treatment did not alter the expression of THR mRNA or THR protein in either control or T3-treated rats." | 1.31 | Effect of amitriptyline on the messenger RNA of thyroid hormone-responsive genes in rat cerebral tissue. ( Li, JP; Mooradian, AD, 2000) |
| "Paroxetine and drug-free treatment did not affect any of these parameters." | 1.31 | Effects of antidepressants on weight and on the plasma levels of leptin, TNF-alpha and soluble TNF receptors: A longitudinal study in patients treated with amitriptyline or paroxetine. ( Haack, M; Hinze-Selch, D; Kraus, T; Kühn, M; Pollmächer, T; Schuld, A; Uhr, M, 2000) |
| " These findings show that chronic administration of low-modest doses of tricyclic antidepressants frequently cause considerable weight gain and can significantly interfere with the ability to provide long-term maintenance therapy." | 1.27 | Weight gain. A side-effect of tricyclic antidepressants. ( Berken, GH; Stern, WC; Weinstein, DO, 1984) |
| "Amitriptyline treatment either caused no change in food intake and body weight or slightly reduced levels in comparison to vehicle-treated controls." | 1.27 | Effects of chronic amitriptyline and desipramine on food intake and body weight in rats. ( Coscina, DV; Nobrega, JN, 1987) |
| "Amitriptyline (AT) was injected i." | 1.27 | Effect of amitriptyline on laminar differentiation of neonatal rat olfactory bulb. ( Chuah, MI; Hui, BS, 1986) |
| "Saccharin intake was increased with lithium treatment as was total caloric intake with sucrose available." | 1.27 | Effects of chronic lithium, amitriptyline and mianserin on glucoregulation, corticosterone and energy balance in the rat. ( Atrens, DM; Gleeson, RM; Higson, FM; Smythe, GA; Storlien, LH, 1985) |
| " Following completion of the dose-response determination for the effect of desipramine or water intake, rats were divided into three groups for repeated administration." | 1.26 | The effect of repeated desipramine administration on water intake in rats. ( O'Donnell, JM; Rider, DP; Seiden, LS; Somani, S, 1982) |
| "In imipramine-treated patients this finding was associated with a decreased rate of drug elimination from plasma." | 1.26 | Relationship between age and tricyclic antidepressant plasma levels. ( Cooper, TB; Friedman, MJ; Green, R; Ives, JO; Nies, A; Ravaris, CL; Robinson, DS, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 57 (79.17) | 18.7374 |
| 1990's | 6 (8.33) | 18.2507 |
| 2000's | 5 (6.94) | 29.6817 |
| 2010's | 4 (5.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, C | 1 |
| Icheva, V | 1 |
| Deppisch, C | 1 |
| Lauer, J | 1 |
| Herrmann, G | 1 |
| Graepler-Mainka, U | 1 |
| Heyder, S | 1 |
| Gulbins, E | 1 |
| Riethmueller, J | 1 |
| Dodick, DW | 1 |
| Freitag, F | 1 |
| Banks, J | 1 |
| Saper, J | 1 |
| Xiang, J | 1 |
| Rupnow, M | 1 |
| Biondi, D | 1 |
| Greenberg, SJ | 1 |
| Hulihan, J | 1 |
| Enginar, N | 1 |
| Nurten, A | 1 |
| Karamürsel, Y | 1 |
| Zengin, A | 1 |
| Baran, E | 1 |
| Boini, KM | 1 |
| Zhang, C | 1 |
| Xia, M | 1 |
| Poklis, JL | 1 |
| Li, PL | 1 |
| Avena-Woods, C | 1 |
| Hilas, O | 1 |
| ARENILLAS, L | 1 |
| Yoshiyama, Y | 1 |
| Kanke, M | 1 |
| Bijl, MJ | 1 |
| Visser, LE | 1 |
| Hofman, A | 1 |
| Vulto, AG | 1 |
| van Gelder, T | 1 |
| Stricker, BH | 1 |
| van Schaik, RH | 1 |
| Rockwell, WJ | 1 |
| Ellinwood, EH | 1 |
| Trader, DW | 1 |
| Claghorn, J | 1 |
| Gershon, S | 1 |
| Goldstein, BJ | 1 |
| Berken, GH | 1 |
| Weinstein, DO | 1 |
| Stern, WC | 2 |
| Mitchell, JE | 1 |
| Groat, R | 1 |
| Davidson, J | 1 |
| Miller, R | 1 |
| Van Wyck Fleet, J | 1 |
| Strickland, R | 1 |
| Manberg, P | 1 |
| Allen, S | 1 |
| Parrott, R | 1 |
| Harto-Truax, N | 1 |
| Miller, LL | 1 |
| Sato, TL | 1 |
| Cato, AE | 1 |
| Agras, WS | 1 |
| Kraemer, HC | 1 |
| Zetin, M | 1 |
| Frost, NR | 1 |
| Brumfield, D | 1 |
| Stone, RA | 1 |
| O'Donnell, JM | 1 |
| Rider, DP | 1 |
| Somani, S | 1 |
| Seiden, LS | 1 |
| Gottfries, CG | 1 |
| Dorman, T | 1 |
| James, B | 1 |
| Cording-Tömmel, C | 1 |
| von Zerssen, D | 1 |
| Williams, W | 1 |
| Peeters, BW | 1 |
| van der Heijden, R | 1 |
| Gubbels, DG | 1 |
| Vanderheyden, PM | 1 |
| Casper, RC | 1 |
| Katz, MM | 1 |
| Bowden, CL | 1 |
| Davis, JM | 1 |
| Koslow, SH | 1 |
| Hanin, I | 1 |
| Szarek, BL | 1 |
| Brandt, DM | 1 |
| Mooradian, AD | 1 |
| Li, JP | 1 |
| Hinze-Selch, D | 1 |
| Schuld, A | 1 |
| Kraus, T | 1 |
| Kühn, M | 1 |
| Uhr, M | 1 |
| Haack, M | 1 |
| Pollmächer, T | 1 |
| Needleman, HL | 1 |
| Waber, D | 1 |
| Coppen, A | 2 |
| Ramo Rao, VA | 1 |
| Swade, C | 1 |
| Wood, K | 1 |
| Lennox, IG | 1 |
| Asbury, JF | 1 |
| Couldrick, WG | 1 |
| Beswick, KB | 1 |
| Ghose, K | 1 |
| Montgomery, S | 1 |
| Rama Rao, VA | 1 |
| Bailey, J | 1 |
| Jorgensen, A | 1 |
| Prusoff, BA | 1 |
| Williams, DH | 1 |
| Weissman, MM | 1 |
| Astrachan, BM | 1 |
| Fruensgaard, K | 1 |
| Hansen, CE | 1 |
| Korsgaard, S | 1 |
| Nymgaard, K | 1 |
| Vaag, UH | 1 |
| Kupfer, DJ | 2 |
| Coble, PA | 1 |
| Rubinstein, D | 1 |
| Pfister, AK | 1 |
| Nies, A | 1 |
| Robinson, DS | 1 |
| Friedman, MJ | 1 |
| Green, R | 1 |
| Cooper, TB | 1 |
| Ravaris, CL | 1 |
| Ives, JO | 1 |
| Nakra, BR | 1 |
| Rutland, P | 1 |
| Verma, S | 1 |
| Gaind, R | 1 |
| Moore, DC | 1 |
| Shibuya, T | 1 |
| Matsuda, H | 1 |
| Endo, T | 1 |
| Chen, PO | 1 |
| Sato, K | 1 |
| Nishimori, T | 1 |
| Bakish, D | 1 |
| Bradwejn, J | 1 |
| Nair, N | 1 |
| McClure, J | 1 |
| Remick, R | 1 |
| Bulger, L | 1 |
| Cohn, CK | 1 |
| Shrivastava, R | 1 |
| Mendels, J | 1 |
| Cohn, JB | 1 |
| Fabre, LF | 1 |
| Claghorn, JL | 1 |
| Dessain, EC | 1 |
| Itil, TM | 1 |
| Lautin, A | 1 |
| Corona, GL | 1 |
| Cucchi, ML | 1 |
| Frattini, P | 1 |
| Santagostino, G | 1 |
| Schinelli, S | 1 |
| Zerbi, F | 1 |
| Savoldi, F | 1 |
| Altamura, AC | 1 |
| De Novellis, F | 1 |
| Guercetti, G | 1 |
| Invernizzi, G | 1 |
| Percudani, M | 1 |
| Montgomery, SA | 1 |
| Hamilton, CA | 1 |
| Barr, SM | 1 |
| Reid, JL | 1 |
| Tekes, K | 1 |
| Tothfalusi, T | 1 |
| Magyar, K | 1 |
| Kassirer, JP | 1 |
| Kopelman, RI | 1 |
| Hoshi, K | 1 |
| Senda, N | 1 |
| Fujino, S | 1 |
| Halmi, KA | 2 |
| Eckert, E | 1 |
| LaDu, TJ | 1 |
| Cohen, J | 1 |
| Nobrega, JN | 1 |
| Coscina, DV | 1 |
| Hecht Orzack, M | 1 |
| Cole, JO | 1 |
| Friedman, L | 1 |
| Bird, M | 1 |
| McEachern, J | 1 |
| Chuah, MI | 1 |
| Hui, BS | 1 |
| Skrumsager, BK | 1 |
| Jeppesen, K | 1 |
| Chouinard, G | 1 |
| Storlien, LH | 1 |
| Higson, FM | 1 |
| Gleeson, RM | 1 |
| Smythe, GA | 1 |
| Atrens, DM | 1 |
| Biederman, J | 1 |
| Herzog, DB | 1 |
| Rivinus, TM | 1 |
| Harper, GP | 1 |
| Ferber, RA | 1 |
| Rosenbaum, JF | 1 |
| Harmatz, JS | 1 |
| Tondorf, R | 1 |
| Orsulak, PJ | 1 |
| Schildkraut, JJ | 1 |
| Fernstrom, MH | 1 |
| Epstein, LH | 1 |
| Spiker, DG | 1 |
| Falk, JR | 1 |
| Tryon, WW | 1 |
| Butler, SH | 1 |
| Weil-Fugazza, J | 1 |
| Godefroy, F | 1 |
| Besson, JM | 1 |
| Lüllmann, H | 1 |
| Lüllmann-Rauch, R | 1 |
| Wassermann, O | 1 |
| Amin, M | 1 |
| Brahm, E | 1 |
| Bronheim, LA | 1 |
| Klingner, A | 1 |
| Ban, TA | 1 |
| Lehmann, HE | 1 |
| Opitz, K | 1 |
| Akinlaja, A | 1 |
| Gluckman, MI | 1 |
| Baum, T | 1 |
| Sedman, G | 1 |
| Paykel, ES | 1 |
| Mueller, PS | 2 |
| De la Vergne, PM | 1 |
| Sethna, ER | 1 |
| Tadokoro, S | 1 |
| Kaneto, H | 2 |
| Koida, M | 2 |
| Tsuchie, F | 2 |
| Miyagawa, H | 1 |
| Collins, AD | 1 |
| Dundas, J | 1 |
| Pieschl, D | 1 |
| Richtberg, W | 1 |
| Brüning, J | 1 |
| Heninger, GR | 1 |
| McDonald, RK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study of Antidepressants in Parkinson's Disease[NCT00086190] | Phase 3 | 115 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Beck Depression Inventory II ranges from 0-63. Higher score indicates more severe depression. 0-13 minimal depression, 14-19 mild depression, 20-28 moderate depression, 29-63 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in BDI-II score (Mean) |
|---|---|
| Paroxetine | -9.7 |
| Venlafaxine Extended Release | -9.6 |
| Placebo | -5.2 |
Brief Psychiatric Rating Scale. Maximum score 126. Higher score indicates greater psychiatric difficulties. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in BPRS score (Mean) |
|---|---|
| Paroxetine | -9.0 |
| Venlafaxine Extended Release | -9.8 |
| Placebo | -4.4 |
Geriatric Depression Scale ranges from 0-30. Higher score indicates more severe depression. 0-9 normal, 10-19 mild depression, 20-30 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in GDS score (Mean) |
|---|---|
| Paroxetine | -6.9 |
| Venlafaxine Extended Release | -6.9 |
| Placebo | -2.8 |
Change in Hamilton Rating Scale for Depression over 12 weeks. Hamilton Depression Rating Scale ranges from 0-50. Higher scores represent more significant depression. Mild depression ranges from 8-13, moderate depression from 14-18, severe 19-22 and very severe any score over 23. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in HAM-D score (Mean) |
|---|---|
| Paroxetine | -13.0 |
| Venlafaxine Extended Release | -11.0 |
| Placebo | -6.8 |
Montgomery-Asberg Depression Rating Scale ranges from 0-60. Higher score indicates more severe depression. 0-6 normal, 7-19 mild depression, 20-34 moderate depression, greater than 34 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in MADRS score (Mean) |
|---|---|
| Paroxetine | -13.6 |
| Venlafaxine Extended Release | -10.9 |
| Placebo | -6.6 |
Parkinson's Disease Questionnaire (PDQ-39) - Emotional Well-Being maximum score 24, minimum score of 0.Lower score indicates a better perceived health status. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in PDQ-39 Emotional score (Mean) |
|---|---|
| Paroxetine | -21.4 |
| Venlafaxine Extended Release | -20.7 |
| Placebo | -10.9 |
Parkinson's Disease Questionnaire (PDQ-39) Total. Range 0-100. Lower score indicates a better perceived health status. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in PDQ-39 score (Mean) |
|---|---|
| Paroxetine | -8.0 |
| Venlafaxine Extended Release | -8.4 |
| Placebo | -5.3 |
Pittsburgh Sleep Quality Index scores range from 0-21, with higher scores indicating severe sleep difficulties. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in PQSI score (Mean) |
|---|---|
| Paroxetine | -2.1 |
| Venlafaxine Extended Release | -2.6 |
| Placebo | -1.1 |
Short Form 36 Health Survey. Range 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 mental score (Mean) |
|---|---|
| Paroxetine | 11.4 |
| Venlafaxine Extended Release | 9.5 |
| Placebo | 4.8 |
Short Form 36 Health Survey - Mental Health subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 Mental Health score (Mean) |
|---|---|
| Paroxetine | 16.7 |
| Venlafaxine Extended Release | 17.4 |
| Placebo | 9.7 |
Short Form 36 Health Survey - Emotional subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 Role score (Mean) |
|---|---|
| Paroxetine | 39.5 |
| Venlafaxine Extended Release | 26.9 |
| Placebo | 12.7 |
Short Form 36 Health Survey - Vitality subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 vitality score (Mean) |
|---|---|
| Paroxetine | 13.5 |
| Venlafaxine Extended Release | 9.1 |
| Placebo | 4.7 |
Snaith Clinical Anxiety Scale. Range 0-21. Higher scores indicate increased anxiety. Score greater than 8 indicates clinical anxiety. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in CAS score (Mean) |
|---|---|
| Paroxetine | -3.6 |
| Venlafaxine Extended Release | -3.2 |
| Placebo | -2.4 |
Unified Parkinson's Disease Rating Scale. Higher score indicates more severe Parkinson's disease symptoms. Total maximum = 176. Mental maximum = 52, Activities of Daily Living maximum = 52, Motor maximum = 72. Minimum = 0. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS score (Mean) |
|---|---|
| Paroxetine | -8.7 |
| Venlafaxine Extended Release | -7.0 |
| Placebo | -4.3 |
Unified Parkinson's Disease Rating Scale - Bulbar maximum score 24, minimum score of 0. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS-Bulbar score (Mean) |
|---|---|
| Paroxetine | -1.4 |
| Venlafaxine Extended Release | -1.4 |
| Placebo | -0.5 |
Unified Parkinson's Disease Rating Scale - Motor has a maximum score of 72, minimum score of 0. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS-motor score (Mean) |
|---|---|
| Paroxetine | -4.3 |
| Venlafaxine Extended Release | -2.0 |
| Placebo | -1.0 |
Unified Parkinson's Disease Rating Scale - Tremor subscale ranges from 0-23. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS-tremor score (Mean) |
|---|---|
| Paroxetine | 0.4 |
| Venlafaxine Extended Release | 0.5 |
| Placebo | -0.6 |
2 reviews available for amitriptyline and Body Weight
| Article | Year |
|---|---|
Psychotropic drugs promoting weight gain: health risks and treatment implications.
Topics: Amitriptyline; Antipsychotic Agents; Body Weight; Chlorpromazine; Energy Intake; Female; Humans; Lit | 1983 |
[Drug-induced phospholipid storage disease].
Topics: Adrenal Gland Diseases; Amitriptyline; Animals; Anticholesteremic Agents; Appetite Depressants; Body | 1973 |
30 trials available for amitriptyline and Body Weight
| Article | Year |
|---|---|
Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs.
Topics: Adult; Amitriptyline; Body Weight; Central Nervous System Agents; Disability Evaluation; Double-Blin | 2009 |
Zimeldine tolerability in comparison to amitriptyline and placebo: findings from a multicentre trial.
Topics: Adult; Aged; Amitriptyline; Blood Pressure; Body Weight; Clinical Trials as Topic; Depressive Disord | 1983 |
A placebo-controlled, double-blind trial of amitriptyline in bulimia.
Topics: Adult; Amitriptyline; Body Weight; Clinical Trials as Topic; Depression; Double-Blind Method; Emotio | 1984 |
A double-blind comparison of bupropion and amitriptyline in depressed inpatients.
Topics: Adult; Amitriptyline; Antidepressive Agents; Appetite; Body Weight; Bupropion; Clinical Trials as To | 1983 |
Effects of bupropion on body weight.
Topics: Amitriptyline; Antidepressive Agents; Appetite; Body Weight; Bupropion; Clinical Trials as Topic; Do | 1983 |
The treatment of anorexia nervosa: do different treatments have different outcomes?
Topics: Adolescent; Amitriptyline; Anorexia Nervosa; Behavior Therapy; Body Weight; Clinical Trials as Topic | 1984 |
Amitriptyline stimulates weight gain in hemodialysis patients.
Topics: Adult; Aged; Amitriptyline; Anorexia Nervosa; Blood Pressure; Body Weight; Clinical Trials as Topic; | 1982 |
Clinical trial comparison of a sustained release form of amitriptyline with dothiepin.
Topics: Adolescent; Adult; Amitriptyline; Body Weight; Clinical Trials as Topic; Delayed-Action Preparations | 1980 |
A double-blind comparative clinical study of amoxapine and amitriptyline in depressed, hospitalised patients.
Topics: Adolescent; Adult; Aged; Amitriptyline; Amoxapine; Body Weight; Cardiovascular Diseases; Clinical Tr | 1982 |
The pattern of physical symptom changes in major depressive disorder following treatment with amitriptyline or imipramine.
Topics: Adult; Affect; Amitriptyline; Appetite; Arousal; Bipolar Disorder; Body Weight; Depressive Disorder; | 1994 |
Zimelidine: a therapeutic and pharmacokinetic study in depression.
Topics: Allylamine; Amitriptyline; Antidepressive Agents; Body Weight; Bridged Bicyclo Compounds; Depression | 1979 |
Viloxazine and amitriptyline in depressive illness. A double blind controlled trial in general practice.
Topics: Adolescent; Adult; Aged; Amitriptyline; Body Weight; Clinical Trials as Topic; Depression; Double-Bl | 1978 |
Continuation therapy with amitriptyline in depression.
Topics: Adult; Aged; Amitriptyline; Body Weight; Clinical Trials as Topic; Depression; Double-Blind Method; | 1978 |
Treatment of secondary depression in schizophrenia. A double-blind, placebo-controlled trial of amitriptyline added to perphenazine.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Amitriptyline; Blood Pressure; Body Weight; Chronic Diseas | 1979 |
Amoxapine versus amitriptyline in endogenous depression. A double-blind study.
Topics: Adult; Aged; Amitriptyline; Amoxapine; Bipolar Disorder; Blood Pressure; Body Weight; Clinical Trial | 1979 |
Changes in weight during treatment for depression.
Topics: Adult; Amitriptyline; Appetite; Body Weight; Depression; Female; Humans; Nortriptyline; Placebos | 1979 |
A comparison of moclobemide, amitriptyline and placebo in depression: a Canadian multicentre study.
Topics: Adult; Amitriptyline; Antidepressive Agents; Benzamides; Body Weight; Canada; Depressive Disorder; F | 1992 |
Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients.
Topics: 1-Naphthylamine; Aged; Aged, 80 and over; Amitriptyline; Body Weight; Depressive Disorder; Drug Ther | 1990 |
Fluoxetine compared with amitriptyline in elderly depression: a controlled clinical trial.
Topics: Aged; Amitriptyline; Appetite; Body Weight; Depressive Disorder; Double-Blind Method; Female; Fluoxe | 1989 |
Anorexia nervosa. Treatment efficacy of cyproheptadine and amitriptyline.
Topics: Adolescent; Adult; Amitriptyline; Anorexia Nervosa; Body Weight; Clinical Trials as Topic; Cyprohept | 1986 |
Weight changes in antidepressants: a comparison of amitriptyline and trazodone.
Topics: Adolescent; Adult; Amitriptyline; Body Weight; Depressive Disorder; Humans; Middle Aged; Trazodone | 1986 |
Femoxetine and amitriptyline in general practice: a randomized double-blind group comparison.
Topics: Adolescent; Adult; Aged; Amitriptyline; Antidepressive Agents; Body Weight; Depressive Disorder; Dou | 1986 |
A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder.
Topics: Adult; Ambulatory Care; Amitriptyline; Anxiety; Body Weight; Clinical Trials as Topic; Depressive Di | 1985 |
Amitriptyline in the treatment of anorexia nervosa: a double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Amitriptyline; Anorexia Nervosa; Body Weight; Child; Double-Blind Method; Humans; | 1985 |
Activity measures in anorexia nervosa.
Topics: Adolescent; Adult; Amitriptyline; Ankle; Anorexia Nervosa; Body Weight; Cyproheptadine; Energy Metab | 1985 |
A double-blind, comparative clinical trial with ludiomil (CIBA 34,276-Ba) and amitriptyline in newly admitted depressed patients.
Topics: Adult; Amitriptyline; Analysis of Variance; Anthracenes; Antidepressive Agents; Blood Pressure; Body | 1973 |
Trial of a sustained release form of amitriptyline (Lentizol) in the treatment of depressive illness.
Topics: Adult; Aged; Amitriptyline; Body Weight; Clinical Trials as Topic; Delayed-Action Preparations; Depr | 1973 |
Amitriptyline, weight gain and carbohydrate craving: a side effect.
Topics: Adult; Amitriptyline; Appetite; Blood Glucose; Body Weight; Clinical Trials as Topic; Depression; Di | 1973 |
A study of refractory cases of depressive illnesses and their response to combined antidepressant treatment.
Topics: Adult; Amitriptyline; Body Weight; Clinical Trials as Topic; Depression; Drug Therapy, Combination; | 1974 |
A double-blind trial of amitriptyline/perphenazine, perphenazine and placebo in chronic withdrawn inert schizophrenics.
Topics: Adult; Affect; Amitriptyline; Analysis of Variance; Body Weight; Chronic Disease; Clinical Trials as | 1967 |
40 other studies available for amitriptyline and Body Weight
| Article | Year |
|---|---|
Long-Term Pulmonal Therapy of Cystic Fibrosis-Patients with Amitriptyline.
Topics: Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Body Weight; Ceramides; Clinical Trials, Pha | 2016 |
Scopolamine-induced convulsions in fasted mice after food intake: evaluation of the sedative effect in the suppression of convulsions.
Topics: Amitriptyline; Animals; Body Weight; Chlorpromazine; Diphenhydramine; Eating; Food Deprivation; Hypn | 2010 |
Role of sphingolipid mediator ceramide in obesity and renal injury in mice fed a high-fat diet.
Topics: Adipose Tissue; Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Blood Pressure; Body Weigh | 2010 |
Antidepressant use in underweight older adults.
Topics: Aged; Aged, 80 and over; Amitriptyline; Antidepressive Agents; Appetite; Body Mass Index; Body Weigh | 2012 |
AMITRIPTYLINE AND BODY-WEIGHT.
Topics: Amitriptyline; Body Weight; Obesity; Toxicology | 1964 |
Influence of hypothyroidism induced by thiamazole on the toxicity of amitriptyline in chick embryos.
Topics: Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Antithyroid Agents; Body Weight; Chick Emb | 2006 |
Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants.
Topics: Aged; Amitriptyline; Antidepressive Agents, Tricyclic; Body Weight; Cohort Studies; Cytochrome P-450 | 2008 |
Weight gain. A side-effect of tricyclic antidepressants.
Topics: Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Appetite; Body Weight; Depressive Disorder; | 1984 |
The effect of repeated desipramine administration on water intake in rats.
Topics: Amitriptyline; Animals; Body Weight; Desipramine; Dose-Response Relationship, Drug; Drinking Behavio | 1982 |
Influence of depression and antidepressants on weight.
Topics: Amitriptyline; Anorexia Nervosa; Antidepressive Agents; Antidepressive Agents, Tricyclic; Appetite; | 1981 |
Mianserin and maprotiline as compared to amitriptyline in severe endogenous depression. A new methodological approach to the clinical evaluation of the efficacy of antidepressants.
Topics: Adult; Amitriptyline; Anthracenes; Body Weight; Depressive Disorder; Dibenzazepines; Drug Evaluation | 1982 |
Possible use of mianserin in cases of unacceptable weight gain due to tricyclic anti-depressant therapy.
Topics: Adult; Amitriptyline; Body Weight; Depression; Dibenzazepines; Female; Humans; Mianserin | 1980 |
Effects of chronic antidepressant treatment on the hypothalamic-pituitary-adrenal axis of Wistar rats.
Topics: Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Body Weight; Corticosterone; Hippocampus; | 1994 |
A comparison of weight changes with fluoxetine, desipramine, and amitriptyline: a retrospective study of psychiatric inpatients.
Topics: Amitriptyline; Body Weight; Desipramine; Dose-Response Relationship, Drug; Drug Therapy, Combination | 1993 |
Effect of amitriptyline on the messenger RNA of thyroid hormone-responsive genes in rat cerebral tissue.
Topics: Adaptor Proteins, Signal Transducing; Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Body | 2000 |
Effects of antidepressants on weight and on the plasma levels of leptin, TNF-alpha and soluble TNF receptors: A longitudinal study in patients treated with amitriptyline or paroxetine.
Topics: Adult; Aged; Amitriptyline; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidep | 2000 |
Letter: Amitriptyline therapy in patients with anorexia nervosa.
Topics: Adolescent; Amitriptyline; Anorexia Nervosa; Body Weight; Child; Female; Humans; Male; Time Factors | 1976 |
Weight gain from combined phenothiazine and tricyclic therapy.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Body Weight; Humans; Pain; Phenothiazines; Thiorida | 1978 |
Relationship between age and tricyclic antidepressant plasma levels.
Topics: Administration, Oral; Adult; Age Factors; Aged; Amitriptyline; Antidepressive Agents, Tricyclic; Bod | 1977 |
Amitriptyline and weight gain: a biochemical and endocrinological study.
Topics: Amitriptyline; Body Weight; Humans; Hyperinsulinism; Hypoglycemia | 1977 |
Amitriptyline therapy in anorexia nervosa.
Topics: Adult; Amitriptyline; Anorexia Nervosa; Body Weight; Compulsive Behavior; Eating; Female; Humans; Re | 1977 |
Pharmacological studies of drug action on CNS, with special reference to effects of maprotiline.
Topics: Action Potentials; Amitriptyline; Animals; Anthracenes; Antiemetics; Apomorphine; Body Weight; Cats; | 1975 |
Aspects of amitriptyline and nortriptyline plasma levels monitoring in depression.
Topics: Adult; Aged; Aging; Amitriptyline; Body Weight; Depressive Disorder; Female; Humans; Middle Aged; Mo | 1990 |
Long-term amitriptyline treatment alters the affinity state of alpha 2 adrenoceptors in rabbit hindbrain.
Topics: Amitriptyline; Animals; Blood Pressure; Body Weight; Brain Stem; Cerebellum; Clonidine; Dioxanes; Ep | 1986 |
Irregular chronic stress related selective presynaptic adaptation of dopaminergic system in rat striatum: effects of (-)deprenyl and amitriptyline.
Topics: Adaptation, Physiological; Amitriptyline; Animals; Body Weight; Corpus Striatum; Dopamine; Male; Mot | 1986 |
Derailed by the availability heuristic.
Topics: Aged; Amitriptyline; Body Weight; Depression; Humans; Male; Marriage; Psychosocial Deprivation; Swea | 1987 |
Effects of perphenazine, diazepam and nitrazepam on amitriptyline metabolism in rat.
Topics: Amitriptyline; Animals; Body Weight; Diazepam; Glucuronosyltransferase; Male; Microsomes, Liver; Nit | 1988 |
Effects of chronic amitriptyline and desipramine on food intake and body weight in rats.
Topics: Amitriptyline; Animals; Body Weight; Deoxyglucose; Desipramine; Feeding Behavior; Female; Infusion P | 1987 |
Effect of amitriptyline on laminar differentiation of neonatal rat olfactory bulb.
Topics: Amitriptyline; Animals; Animals, Newborn; Body Weight; Cholinergic Fibers; Olfactory Bulb; Rats; Rat | 1986 |
Effects of chronic lithium, amitriptyline and mianserin on glucoregulation, corticosterone and energy balance in the rat.
Topics: Amitriptyline; Animals; Blood Glucose; Body Weight; Corticosterone; Dibenzazepines; Drinking; Eating | 1985 |
Resting metabolic rate is reduced in patients treated with antidepressants.
Topics: Adult; Amitriptyline; Antidepressive Agents; Body Weight; Depressive Disorder; Drug Therapy, Combina | 1985 |
Reduction of arthritis and pain behaviour following chronic administration of amitriptyline or imipramine in rats with adjuvant-induced arthritis.
Topics: Amitriptyline; Animals; Arthritis; Arthritis, Experimental; Behavior, Animal; Body Weight; Disease M | 1985 |
[On the influencing of food intake by psychotropic drugs].
Topics: Amitriptyline; Animals; Behavior, Animal; Body Weight; Central Nervous System; Central Nervous Syste | 1966 |
The pharmacology of iprindole, a new antidepressant.
Topics: Acetylcholine; Amitriptyline; Amphetamine; Animals; Antidepressive Agents; Appetite; Atropine; Bleph | 1969 |
[Behavioral and pharmacological studies on doxepin, a tricyclic agent. 2. Changes in conditional behaviors after repeated administration of doxepin].
Topics: Administration, Oral; Amitriptyline; Animals; Behavior, Animal; Body Weight; Conditioning, Operant; | 1972 |
[Tolerance and physical dependence producing liability of doxepin].
Topics: Amitriptyline; Animals; Body Weight; Diazepam; Dibenzoxepins; Drug Resistance; Humans; Imipramine; M | 1972 |
[Screening procedure for barbital type physical dependence liability of psychotropic drugs in mice].
Topics: Amitriptyline; Animals; Barbiturates; Behavior, Animal; Benzazepines; Benzodiazepinones; Body Weight | 1973 |
Editorial: Drugs causing weight gain.
Topics: Amitriptyline; Appetite; Blood Glucose; Body Weight; Chlorpromazine; Depression; Dietary Carbohydrat | 1974 |
[Saroten retard and its therapeutic possibilities in chronic schizophrenic psychoses. Results of clinical-experimental tests].
Topics: Adult; Amitriptyline; Body Weight; Cardiovascular Diseases; Chronic Disease; Delayed-Action Preparat | 1971 |
Intravenous glucose tolerance test in depression.
Topics: Adult; Age Factors; Aged; Amitriptyline; Bipolar Disorder; Blood Glucose; Body Weight; Depression; F | 1969 |